Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series A
Biotech
Solstice rises with $225M series A for next-gen CTLA-4 therapy
Solstice Oncology has secured $225 million to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.
Will Maddox
Sep 9, 2026 7:00am
Schrödinger births new immunology focused biotech, Tectora
Sep 9, 2026 7:00am
Beeline bolsters autoimmune ambitions with $126M
Jun 30, 2026 7:00am
Tortugas comes out of shell with $106M, 4 ph. 2-stage neuro meds
Apr 21, 2026 10:41am
Early-stage funding slump puts more pressure on biotech startups
Apr 16, 2026 7:00am
Bain-backed Beeline buzzes out of stealth with $300M
Apr 15, 2026 7:00am
